Mylan Inc. said Monday it started shipping a generic version of the antidepressant Wellbutrin SR after getting approval from the Food and Drug Administration.
The FDA cleared Mylan's version of the drug in 100 milligram, 150 milligram and 200 milligram doses, Mylan said. The brand-name version of Wellbutrin SR is made by GlaxoSmithKline, and U.S. sales totaled $363 million in 2009.
Wellbutrin SR is the extended-release version of Wellbutrin, an older GlaxoSmithKline drug. Mylan is conducting what is called an "at-risk launch" because the patents on Wellbutrin SR do not expire until August 2013. At-risk launches usually result in patent lawsuits.
In midday trading, Mylan stock rose 3 cents to $22.58. Shares of GlaxoSmithKline rose 4 cents to $39.24.